Careers  |  Sign In  |  Register
Series Progress
Part 1
Part 2
Part 3
Part 4

Part 3

Utilizing Incretin-based Therapies in Combination with Insulin and Oral Agents

Free CME

Downloadable Education Resources

Sponsorship Statement

These continuing medical education activities are sponsored by

Vindico Medical Education

Support Statement

These activities are supported by an educational grant from:

Bristol-Myers SquibbAstraZenecaAdvancing Diabetes Care

Target Audience

The intended audience for these activities are endocrinologists and other healthcare professionals involved in the treatment of patients with type 2 diabetes.

Learning Objectives

At the conclusion of this series participants should be able to:

  • Assess the pathophysiology of hyperglycemia, its role in macro and microvascular diseases, and the role of incretin pathways in type 2 diabetes mellitus.
  • Examine the differences in mechanism of action, efficacy, and safety of treatment options that target the incretin pathway.
  • Incorporate evidence-based guidelines and recommendations into practice when considering the use of incretin-based therapies for type 2 diabetes.
  • Examine approaches to managing the obese patient with type 2 diabetes.
  • Utilize GLP-1 agonists and DPP-IV inhibitors in combination with insulin and oral agents to achieve optimal glycemic control.
  • Analyze the potential cardiovascular benefits of incretin therapies in addition to glycemic control.


This eJournal series consists of expert commentary and key highlights from the Editorial Board of the CME publication series Dialogues in Diabetes, mailed in conjunction with Endocrine Today, in September, October, November and December 2013.


Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit Department of Endocrinology Ochsner Medical Center New Orleans, LA

Michael H. Davidson, MD, FACC, FACP, FNLA Professor, Director of the Lipid Clinic The University of Chicago, Pritzker School of Medicine Chicago, IL

Ralph A. DeFronzo, MD Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center of San Antonio Deputy Director Texas Diabetes Institute San Antonio, TX

Vivian A. Fonseca, MD, FRCP Professor of Medicine and Pharmacology Tullis–Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, LA


Ronald A. Codario, MD, FACP, CCMEP

Carol H. Wysham, MD


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release: November 18, 2013 to November 17, 2014.

How To Participate in this Activity and Obtain CME Credit

To participate in these CME activities, you must read the objectives, answer the pretest questions, watch the presentations, complete the CME posttests, and complete the evaluations. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of each of videos posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support. Planning Committee and Faculty members report the following relationship(s):

Lawrence Blonde, MD, FACP, FACE Research Grant Support: To Ochsner for his role as investigator from Eli Lilly and Company, Novo Nordisk, and Sanofi-Aventis Speaker’s Bureau: Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb/AstraZeneca, Janssen Pharmaceuticals, Inc., Johnson & Johnson Diabetes Institute, L.L.C., Merck & Co. Inc., Novo Nordisk, Sanofi-Aventis, Santarus, Vivus, Inc. Consultant: Amylin Pharmaceuticals, Inc., Eisai Inc, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi-Aventis, Santarus

Michael H. Davidson, MD, FACC, FACP, FNLA Consulting Fees: AbbVie, Amgen, AstraZeneca, Daiichi-Sankyo, Esperion, Lipidemx, Merck & Co., Inc. Speakers Bureau: Merck & Co., Inc. Ownership Interest: Prior to July 2013, ownership interest in Omthera Pharmaceuticals, Inc.

Ralph A. DeFronzo, MD Consulting Fees: Amylin, Bristol-Myers Squibb, Janssen, Lexicon, Novo Nordisk, Takeda Contracted Research: Amylin, Bristol-Myers Squibb, Lexicon, Takeda Speakers Bureau: Amylin, AstraZeneca, Bristol Myers Squibb, Janssen, Novo Nordisk

Vivian A. Fonseca, MD, FRCP Honoraria for Consulting Fees and Lectures: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Novo Nordisk, PamLabs, Sanofi-Aventis, Takeda Research Support (to Tulane): Abbott, Eli Lilly, Endo Barrier, Novo Nordisk, Pan American Laboratories, Rcata, Sanofi-Aventis

Robert R. Henry, MD(Planning Committee only) Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis Consultant: Boehringer Ingelheim, Intarcia, Isis, Eli Lilly, Novo Nordisk, Roche/Genentech, Sanofi-Aventis Advisory Board: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Elcelyx, Eli Lilly, Intarcia, Johnson & Johnson/Janssen, Merck & Co., Inc., Novo Nordisk, Roche/Genentech, Sanofi-Aventis

Reviewers report the following relationship(s):

Ronald A. Codario, MD, FACP, CCMEP No relevant financial relationships to disclose.

Carol H. Wysham, MD Consulting Fees: Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi-Aventis Speaker’s Bureau: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Novo Nordisk, Sanofi-Aventis Contract Research: Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Intarcia, Janssen, Merck & Co., Inc., Novo Nordisk, Sanofi-Aventis

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

BetterCME staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance. Unlabeled and Investigational Usage: The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices. Copyright Statement: Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013. Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.